"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An organoplatinum compound that possesses antineoplastic activity.
Descriptor ID |
D016190
|
MeSH Number(s) |
D02.691.800.338
|
Concept/Terms |
Carboplatin- Carboplatin
- cis-Diammine(cyclobutanedicarboxylato)platinum II
- CBDCA
|
Below are MeSH descriptors whose meaning is more general than "Carboplatin".
Below are MeSH descriptors whose meaning is more specific than "Carboplatin".
This graph shows the total number of publications written about "Carboplatin" by people in this website by year, and whether "Carboplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 0 | 1 | 1 |
1996 | 0 | 2 | 2 |
1997 | 0 | 2 | 2 |
1998 | 0 | 2 | 2 |
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2001 | 0 | 2 | 2 |
2002 | 0 | 3 | 3 |
2003 | 1 | 5 | 6 |
2004 | 0 | 3 | 3 |
2005 | 0 | 5 | 5 |
2006 | 0 | 4 | 4 |
2007 | 1 | 4 | 5 |
2008 | 1 | 11 | 12 |
2009 | 1 | 6 | 7 |
2010 | 1 | 5 | 6 |
2011 | 4 | 15 | 19 |
2012 | 3 | 3 | 6 |
2013 | 0 | 3 | 3 |
2014 | 0 | 1 | 1 |
2015 | 1 | 5 | 6 |
2016 | 3 | 2 | 5 |
2017 | 3 | 2 | 5 |
2018 | 0 | 9 | 9 |
2019 | 1 | 8 | 9 |
2020 | 1 | 4 | 5 |
2021 | 4 | 9 | 13 |
2022 | 0 | 6 | 6 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carboplatin" by people in Profiles.
-
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023 12; 186:107418.
-
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO Precis Oncol. 2023 Sep; 7:e2300235.
-
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 12 01; 40(34):3965-3974.
-
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
-
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2023 01 01; 41(1):107-116.
-
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol. 2022 09; 17(9):1122-1129.
-
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 04 20; 40(12):1323-1334.
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.